U.S. markets open in 8 hours 27 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1371-0.0109 (-7.36%)
At close: 1:41PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1480
Open0.1365
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1365 - 0.1500
52 Week Range0.0940 - 0.6045
Volume151,214
Avg. Volume117,748
Market Cap36.91M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tetra Bio-Pharma Provides Update on Recent Milestones
    ACCESSWIRE

    Tetra Bio-Pharma Provides Update on Recent Milestones

    * Plenitude Trial initiated * Tetra completes clinical study assessing the metabolism profile of cannabinoids in humans * Achieved development of ARDS-003 sterile injectable nano-emulsion for human useOTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc.

  • Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003
    ACCESSWIRE

    Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003

    * Initial Drug Indication Targets COVID-19 Related Survival Benefits * Cost-Saving Including When Used With a Remdesivir™ Standard of Care * Expanded Post-Survival Indications (Reduce the Risk of Fibrosis and Multi-Organ Dysfunctions) * Tetra Estimates Potential Revenues From Royalties on Net Sales, Milestone and Upfront Payments of Over $500 Million USD by 2026OTTAWA, ON / ACCESSWIRE / November 4, 2020 / Tetra Bio-Pharma Inc.

  • CNW Group

    Tetra Bio-Pharma Inc. Acquires Common Shares of Mondias Natural Products Inc.

    OTTAWA, ON, Nov. 2, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc.